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Abstract
Background: T cells play a dominant role in the pathogenesis of asthma. Costimulation of T cells
is necessary to fully activate them. An inducible costimulator (ICOS) of T cells is predominantly
expressed on Th2 cells. Therefore, interference of signaling pathways precipitated by ICOS may
present new therapeutic options for Th2 dominated diseases such as asthma. However, these
signaling pathways are poorly characterized in vitro and in vivo.
Methods:  Human primary CD4+ T cells from blood were activated by beads with defined
combinations of surface receptor stimulating antibodies and costimulatory receptor ligands. Real-
time RT-PCR was used for measuring the production of cytokines from activated T cells. Activation
of mitogen activated protein kinase (MAPK) signaling pathways leading to cytokine synthesis were
investigated by western blot analysis and by specific inhibitors. The effect of inhibitors in vivo was
tested in a murine asthma model of late phase eosinophilia. Lung inflammation was assessed by
differential cell count of the bronchoalveolar lavage, determination of serum IgE and lung histology.
Results: We showed in vitro that ICOS and CD28 are stimulatory members of an expanding family
of co-receptors, whereas PD1 ligands failed to co-stimulate T cells. ICOS and CD28 activated
different MAPK signaling cascades necessary for cytokine activation. By means of specific inhibitors
we showed that p38 and ERK act downstream of CD28 and that ERK and JNK act downstream of
ICOS leading to the induction of various T cell derived cytokines. Using a murine asthma model of
late phase eosinophilia, we demonstrated that the ERK inhibitor U0126 and the JNK inhibitor
SP600125 inhibited lung inflammation in vivo. This inhibition correlated with the inhibition of Th2
cytokines in the BAL fluid. Despite acting on different signaling cascades, we could not detect
synergistic action of any combination of MAPK inhibitors. In contrast, we found that the p38
inhibitor SB203580 antagonizes the action of the ERK inhibitor U0126 in vitro and in vivo.
Conclusion: These results demonstrate that the MAPKs ERK and JNK may be suitable targets for
anti-inflammatory therapy of asthma, whereas inhibition of p38 seems to be an unlikely target.
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Background
Asthma is a chronic inflammatory disease of the airways.
The inflammation characterizing asthma is complex and
involves multiple cells and mediators. The cells involved
include well-recognized immune and inflammatory cells,
lymphocytes, macrophages, eosinophils, mast cells and
neutrophils as well as resident lung cells [1,2]. The impor-
tance of allergen-specific CD4+ Th2 cells has been demon-
strated. Th2-associated cytokines such as IL-4, IL-5, IL-9
and IL-13 are known to be involved in IgE production, air-
way eosinophilia, and airway hyperresponsiveness [3].
Consequently, the inhibition or modulation of allergen-
specific Th2 cells and their cytokines has become an
attractive target for novel therapeutic intervention strate-
gies [4-6]. Downregulation of cytokine production has
been achieved by glucocorticoids and immunosuppres-
sants both in vitro and in vivo. As these agents suppressed
a broad spectrum of immune function, more specific reg-
ulatory pathways of T cell need to be addressed.
In recent years, considerable effort has been mounted to
dissect the signaling events in T cells. Full activation of T
cells requires signaling through both the TCR/CD3 com-
plex and the CD28 costimulatory receptor [7-10]. CD28
engagement by B7-1 and B7-2 on resting T cells provides
a primary costimulatory signal critical for initial cell cycle
progression, interleukin 2 production and clonal expan-
sion [11]. Engagement of CTLA-4 by the same B7-1 or B7-
2 ligands results in attenuation of T cell responses.
Recently, molecular homologues of CD28 and CTLA-4
coreceptors and their B7-like ligands have been identified.
These homologues presumably play an essential role in
the acquisition of effector function and/or tolerance
induction. One of the CD28-like molecules is induced
during activation of T cells, thus it is referred as an induc-
ible costimulator (ICOS) and has a unique B7-like ligand
(B7-H2, B7 h or B7RP-1). PD-1 is an inhibitory CD28-like
receptor, with two B7-like ligands (PD-L1 and PD-L2)
[12,13]. It has been shown that the ICOS/B7-H2 pathway
controls T cell dependent immune responses [14-17].
Several protein kinases such as the family of MAPKs are
involved in the transmission of extracellular signals into
the nucleus. [18]. MAPKs are serine/threonine kinases
that include extracellular signal-regulated kinases (ERKs)
[19], Jun NH2-terminal kinases (JNKs) [20] and p38
MAPK [21]. CD3 signaling alone has been shown to acti-
vate ERK, and the combination of CD3 and CD28 signal-
ing can synergistically activate JNK in T cell lines and
clones [22,23]. In these studies, CD28 signaling alone was
shown to minimally activate ERK and JNK, while others
have reported much more significant ERK activation [24].
Activation of p38 has also been observed in Jurkat cells
and in mouse T cells treated with CD3/CD28 [25,26].
While it has become clear that productive T cell activation
requires the cooperation of multiple signaling pathways,
the composition and the relative contribution of these
pathways to the activation process and cytokine produc-
tion remain yet to be fully deciphered.
The predominant expression of ICOS on Th2 cells and its
effect on the development of Th2 cells has been reported
[15,27]. Therefore, interference of signaling pathways pre-
cipitated by ICOS may present new therapeutic options
for Th2 dominated diseases such as asthma. However,
these signaling pathways are poorly characterized.
Recently, we reported that the ERK pathway plays a piv-
otal role in regulating IL-13 production in human CD4+ T
cells after CD28 costimulation [28]. In the present study,
we studied the activation of different MAP kinases in
human CD4+ T cells stimulated by α -CD3/α -ICOS, their
function in the production of cytokines from these cells
and compared these results to α -CD3/α -CD28 stimulated
T cells. Our results demonstrate, that in human CD4+ T
cells, p42/p44 ERK, p38 and JNK differentially regulate
the production of IL-2, IL-4, IL-13 and IFN-γ  in response
to  α -CD3/α -CD28 or α -CD3/α -ICOS. Furthermore,
inhibitors able to inhibit ICOS induced signaling proved
to be effective in the murine asthma model of late phase
eosinophilia.
Methods
Reagents
Oligonucleotides were synthesized by TIB Molbiol (Ber-
lin, Germany). DMSO, TPA, ionomycin, dexamethasone,
Histopaque-1077 was from Sigma Chemical Co (Deisen-
hofen, Germany). U0126, SP600125 and SB203580 were
purchased from Biotrend Chemikalien GmbH (Köln, Ger-
many). Purified anti-human CD3 and purified anti-
human CD28 were from PharMingen Becton Dickinson
Co (Heidelberg, Germany). RPMI 1640 medium was
from Life Technologies (Heidelberg, Germany). Unless
otherwise indicated, all other chemicals were purchased
from the Sigma Chemical Co (Deisenhofen, Germany).
Preparation of CD4+ T cells
Buffy coats from healthy human volunteers were obtained
from the Erlangen Blood Bank. PBMCs were isolated by
density gradient centrifugation over Histopaque 1077
(Sigma, Deisenhofen, Germany), washed twice in Hanks
buffer (Life Technologies, Heidelberg, Germany) and
resuspended in RPMI 1640 medium (Roche Diagnostics,
Penzberg, Germany). PBMCs were incubated with a hap-
ten-antibody cocktail (containing monoclonal hapten-
conjugated CD8, CD11b, CD16, CD19, CD36 and CD56
antibodies, Miltenyi Biotec, Bergisch Gladbach, Ger-
many) and MACS anti-hapten microbeads (CD4+ T cell
isolation kit, Miltenyi Biotec, Bergisch Gladbach, Ger-
many). CD4+ T cells were isolated by negative selection on
LS+ columns using a high gradient magnetic cellRespiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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separation system MACS (Miltenyi Biotec, Bergisch Glad-
bach, Germany) according to the manufacturer's instruc-
tions. Purity of CD4+  T cells was assessed by flow
cytometry and was 90–95% (FACScan, Becton Dickinson,
Heidelberg, Germany). Additional cells were monocytes
(4–8%) and B cells (1–2%), which did not respond to α -
CD3 antibodies. Purified CD4+ T cells were resuspended
in RPMI 1640 medium.
Cell culture
For cytokine production, CD4+ T cells were resuspended at
0.25 × 106 cells/ml and incubated in 500 µl aliquots in 24-
well tissue culture plates (Falcon Becton Dickinson
Labware, Heidelberg, Germany) at 37°C, 5%CO2. After
preincubation with test substances for 30 min, cells were
stimulated with α -CD3/α -CD28 Dynal beads (8*104/2
µl/well). B7-H1, B7-H2 and B7-H3 binding by their recep-
tors was assessed by stimulation of the cultured cells with
self coated Dynabeads M-450 Epoxy (Dynal Biotech
GmbH, Hamburg, Germany). α -CD3 mAb (0.1 µg/µl)
(Pharmingen, Heidelberg, Germany) together with 0.04
µg/µl recombinant fusion proteins of B7-H1, B7-H2 and
B7-H3 respectively, (R&D, Wiesbaden-Nordenstadt, Ger-
many), were added to the prewashed beads according to
the manufacturer's recommendations. The beads were
added at a ratio of 3:1 to the CD4+ T cells. At the indicated
times (presented in figure legends), cells were sedimented
by centrifugation, the supernatants were harvested and
kept frozen at -80°C until cytokine protein determina-
tion; the cell pellet was lysed by RLT lysis buffer (Qiagen,
Hilden, Germany) and frozen at -80°C until RNA
isolation.
Enzyme-linked immunosorbent assay
Cytokine measurements in culture supernatants were
done by sandwich ELISA using matched antibody pairs
(BD Pharmingen, Heidelberg, Germany). ELISA plates
(Maxisorb, Nunc) were coated overnight with anti-
cytokine mAb in 0.1 M carbonate buffer, pH 9.5. After
being washed, plates were blocked with Assay Diluent
(Pharmingen, Heidelberg, Germany) for 1 h and washed
again. Appropriately diluted supernatant samples and
standards were distributed in duplicates and the plates
were incubated for 2 h at room temperature. Plates were
washed, incubated for 1 h with working detector (bioti-
nylated anti-cytokine Ab and Avidin-horseradish peroxi-
dase conjugate). After washing, substrate (TMB and
hydrogen peroxide) was added. The reaction was stopped
by addition of 1 M H3PO4. Plates were read at 450 nm
(reference 570 nm) in a microplate reader (Dynatech).
The results were expressed as a percentage of the control
level of cytokines production by cells stimulated in the
presence of the vehicle of the corresponding compound.
Determination of serum levels of total and OVA-specific 
IgE
Serum levels of OVA-specific IgE were measured by IgE
ELISA (OptEIA, BD Pharmingen). Briefly, 96-well plates
(Maxisorb, Nunc) were coated with OVA (100 µg/ml).
After addition of serum samples, a sheep anti-IgE Ab was
added to individual wells and its binding was detected
with peroxidase-conjugated anti-sheep IgG. IgE concen-
trations were calculated by comparison with commercial
mouse IgE standards (BD Pharmingen).
Analysis of cytokine mRNA expression by real-time RT-
PCR
RNA was prepared from frozen lysates using Rneasy (QIA-
GEN, Hilden, Germany). One-tube RT-PCR was per-
formed using Quantitect Probe RT-PCR Kit from QIAGEN
(Hilden, Germany). Expression of cytokines were deter-
mined in relation to beta-actin by real time RT-PCR using
TaqMan assay on a ABI Prism 7900. Human primers and
probes have been described [6]. Murine primers and
probes were Assay-On-Demand purchased from Applied
Biosystems (Darmstadt, Germany). Quantity of mRNA
was calculated using the ∆∆ CT method (PE Applied Bio-
systems User Bulletin #2; ABI PRISM 7700 Sequence
Detection System, 1997). For each RT-PCR the threshold
cycle (CT) was determined, being defined as the cycle at
which the fluorescence exceeds 10 times the standard
deviation of the mean baseline emission for cycles 3 to 10.
Cytokine mRNA levels were normalized to the house-
keeping gene β -actin according to the following formula:
∆ CT  = CT
β -actin  - CT
cytokine. Subsequently, respective
cytokine mRNA levels were calculated using the ∆∆ CT
method, i.e., ∆ CT values representing mRNA from cells
treated with stimulus in combination with a test com-
pound were set in relation to the ∆ CT value representing
mRNA levels from cells treated with stimulus alone
according to the following formula: ∆∆ CT = ∆ CT(drug) -
∆ CT(vehicle). The relative mRNA level for the respective
test compound was calculated as 2-∆∆ C
T * 100% based on
the results of control experiments with an efficiency of the
PCR reaction of approximately 100%.
Western Blotting analysis of the MAPKs
Human CD4+ T cells were stimulated with Dynabeads
CD3/CD28 T Cell Expander (Dynal Biotech GmbH, Ham-
burg, Germany) or with Dynal beads coated with α -CD3/
B7-H2 Fc for 0, 5, 15, 60 or 120 min. After stimulation,
cells were washed with ice-cold PBS and lysed in cell lysis
buffer (Tris 50 mM, pH 7.2, containing 10 mM EDTA, 150
mM NaCl, 1% NaDOC, 0.1% SDS, 1% Triton X-100) sup-
plemented with protease inhibitors (1 mM PMSF, 5 µg/µl
Aprotinin and 5 µg/µl Leupeptin). Cells were left on ice
for 20 min and then centrifuged at 14.000 rpm for 10
min. The supernatants were stored at -80°C until meas-
urement of the MAPKs. Equal amounts of protein wereRespiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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resolved in 10% SDS-polyacrylamid gel electrophoresis
and transferred onto PVDF membrane. Membranes were
blocked overnight at 4°C with 0.2 % I-block (Applied Bio-
systems, Darmstadt, Germany) in TBS/T buffer and
probed with rabbit primary antibodies specific for the
dually phosphorylated active forms of ERK, p38 and JNK
(Promega GmbH, Mannheim, Germany) for 2 h at room
temperature. Blots were washed, incubated 1 h at room
temperature with second antibody (donkey anti-rabbit
horseradish peroxidase conjugated) (Promega GmbH,
Mannheim, Germany). Immunoreactive bands were visu-
alized by enhanced chemiluminiscence (ECL) according
to the manufacturer's recommendations (Amersham
Pharmacia Biotech, Freiburg, Germany). After detection
of the active form of the MAPK, membranes were stripped
and reprobed with the corresponding antibody that recog-
nize both active and inactive forms of p38, JNK (Santa
Cruz Biotechnology, Inc., Heidelberg, Germany) and ERK
(Promega GmbH, Mannheim, Germany).
ELISA detection of activated JNK
The FACE (Fast Activated Cell-based ELISA) kit (Active
Motif, Rixensart, Belgium) was used according to the pro-
vider's protocol. CD4+ T cells were cultured in precoated
(poly-L-lysine) (Sigma, Deisenhofen, Germany) 96-well
plates at a concentration of 1 × 106 /ml and were stimu-
lated with α -CD3/α -CD28 and α -CD3/B7-H2 Fc for dif-
ferent time points (1 min, 5 min, 15 min, 60 min and 120
min) to induce the JNK pathway. Following stimulation
the cells were fixed in order to preserve protein modifica-
tions, including phosphorylation. Corresponding wells
were then incubated with a primary antibody specific for
pJNK and total JNK respectively. Subsequent incubation
with secondary HRP-conjugated antibody and developing
solution was followed by a colorimetric detection. The
signals were then normalized for cell number using Crys-
tal Violet.
Murine model of late phase eosinophilia
Male Balb/c mice weighing 22–25 g were used. Animals
were purchased from Harlan (Borchen, Germany). The
animals were kept under constant environmental condi-
tions (temperature: 18 ± 2°C, humidity: 40–60 %, light
cycle: 7 am – 7 pm). They had free access to standardized
food pellets (purchased from Altromin, Lage, Germany)
and tap water. All animal studies were performed in
accordance with the national animal protection rules and
permitted by the local governmental authority (Regierung
von Mittelfranken, Germany). The sensitization strategy
was adapted from previously described mouse model
[29]. Briefly, all Balb/c mice were actively immunized and
boosted by intraperitoneal injections with 200 µl of a
solution containing 100 µg ovalbumin (grade V, Sigma,
Taufkirchen, Germany) adsorbed on 4 mg of an aqueous
solution of aluminium hydroxide and magnesium
hydroxide (Alum) (Perbio Science, Bonn, Germany) on
days 1, 14 and 20. On day 26, the animals were used for
experiments. Compounds, as suspension in 5% DMSO,
were given intraperitoneally two hours prior to challenge
once a day. Control animals (negative and positive)
received only vehicle solution. Mice were challenged twice
a day for 4 days by intranasal application of 50 µl of 2 µg/
µl ovalbumin solution in NaCl to provoke an influx of
inflammatory cells into the airways. Negative control
mice were sensitized intraperitoneally with OVA/Alum
and were challenged intranasally with saline solution.
Positive control animals were sensitized as mentioned
above and challenged intranasally with ovalbumin. On
day 30 animals were sacrificed by putting them into a CO2
rich atmosphere and a bronchoalveolar lavage (BAL) was
performed by flushing the lungs and the airways six times
with 0.5 ml Hank's balanced solution (Gibco, Karlsruhe,
Germany) supplemented with Na-EDTA and HEPES
(Sigma, Taufkirchen, Germany). The number of eosi-
nophils as well as the total cell number from the pooled
BAL samples of one animal was counted using a haemo-
cytometer (Sysmex microcellcounter F-300, Norderstedt,
Germany). BAL cells were spun onto glass slides using a
cytospin centrifuge and stained with Diff-Quik (Dade-
Behring, Marburg, Germany). The percentage and number
of eosinophils were determined microscopically using
standard cytological (morphological and staining) criteria
by counting 400 cells/slide. Each group of animals treated
with compounds was compared with saline challenged
(negative control) and vehicle-treated ovalbumin chal-
lenged (positive control) groups. For RNA analysis cells
recovered from broncheoalveolar lavage were sedimented
by centrifugation and RNA was prepared from the cell
pellet.
Histological examination of lungs
Lungs removed from the chest were instilled intratrache-
ally with 0.8 ml 4% buffered formalin solution and
immersed in this fixative for 48 hours. Tissues were
embedded in paraffin and sections of 5 µm were cut.
Slices were stained with May-Grünwald Giemsa for exam-
ining inflammation and eosinophilic infiltration and
periodic acid-Schiffs stain was done for measuring mucus
production under the light microscope. To determine the
severity of peribronchial inflammation a semiquantita-
tively score described by Myou et al. [30] was determined.
Briefly, this score describes followingcategories: 0, no
inflammation; 1, few inflammatory cells; 2, a ring of
inflammatorycells 1 cell layer deep; 3, a ring of inflamma-
tory cells 2–4 cells deep; 4, a ring of inflammatory cells of
>4 cells deep. The numerical scores for the abundance of
PAS-positive mucus-containingcell in each airway were
adapted from the same reference as follows: 0, <0.5%PAS-
positive cells; 1, 5–25%; 2, 25–50%; 3, 50–75%;4, >75%.Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
Page 5 of 19
(page number not for citation purposes)
Data analysis
Data are expressed as means ± s.e.mean. Significant differ-
ences were statistically analyzed by the unpaired Student's
t-test and by ANOVA. IC50 and ED50 values were calculated
using the computer program PRISM 3.0 (GraphPad Soft-
ware Inc., San Diego, CA, U.S.A).
Results
Influence of coreceptors on TCR induced cytokine 
expression in CD4+ T cells
The stimulation of human CD4+ T cells by beads coated
with α -CD3 antibodies and various ligands for corecep-
tors was compared. For our studies, we developed a real-
time RT-PCR method for accurate quantization of T cell
cytokines. Cells were stimulated with beads coated with
α -CD3 alone, α -CD3 plus α -CD28, α -CD3 plus B7-2 Fc
fusion protein, α -CD3 plus B7-H2 Fc fusion protein, α -
CD3 plus PD-1 ligand Fc fusion protein (PD-L1 or B7-H1)
or  α -CD3 plus B7-H3 Fc fusion protein. Naked beads
alone were included as a negative control and did not acti-
vate CD4+ T cells. IL-5 mRNA was not induced by any
stimulation condition. In contrast, IL-2, IL-4, IL-10, IL-13
and IFNγ  mRNA expression was already stimulated by α -
CD3 activation alone and maximally stimulated by α -
CD3/α -CD28 activation, which was included as a positive
control (Figure 1A). B7-2 and B7-H2 binding to their
respective counterreceptors costimulated cytokine gene
expression to elevated levels compared to α -CD3 activa-
tion alone. Costimulation strength by ICOS ligation was
comparable to CD28 costimulation. In contrast, B7-H1
and B7-H3 mediated costimulation did not augment α -
CD3 induced cytokine mRNA levels (Figure 1A). To sub-
stantiate these results, cytokine protein concentration of
the prototypic cytokines IL-2, IL-4 and IFN  was deter-
mined in stimulated CD4+ T cell supernatants (Figure 1B).
The pattern was similar to the induction on the mRNA
level. B7-2 and B7-H2 costimulation produced more
cytokines than α -CD3 stimulation alone. B7-2 was more
effective in costimulation that B7-H2 (Figure 1B). Simi-
larly, B7-H1 and B7-H3 mediated costimulation did not
augment α -CD3 induced cytokine protein levels (data not
shown).
Time course of cytokine induction in CD4+ T cells
Since CD28 and ICOS were the only stimulating corecep-
tors, they were chosen to study the time course of cytokine
mRNA induction. As can be seen from figure 2A, α -CD3/
B7-2 stimulation induced cytokine mRNA levels rapidly
till two hours. Whereas IL-13 mRNA levels started to
decline from that time point on, other cytokine mRNA
levels still increased. Similar observations were made after
α -CD3/B7-H2 stimulation (Figure 2B). Most remarkable,
IL-13 and IFNγ  were more strongly induced as compared
to  α -CD3/B7-2 stimulation, whereas IL-2 was much
weaker induced. The induction of IL-10 was weak for both
costimulatory receptors.
Activation of MAPKs by costimulatory receptors
We speculated that differential activation of MAPK family
members by CD28 and ICOS may contribute to their dif-
ferent cytokine production patterns. To this end, we inves-
tigated the activation of the MAPK family members as
downstream signaling molecules. T cell receptor and B7-2
(Figure 3A) or B7-H2 (Figure 3B) cross-linking elicited the
phosphorylation of ERK and p38 indicating the up-regu-
lation of kinase activity. The activation reached a maxi-
mum 15 min after B7-2 costimulation and 2 min after B7-
H2 costimulation for both kinases. It persisted over a
period of two hours. Since we could not detect JNK by
western blot, we analyzed JNK activation by a recently
available ELISA method. A cell-based ELISA method was
used to determine the JNK phosphorylation relative to the
total JNK protein found in CD4+ T cells. Stimulation with
α -CD3/α -CD28 and α -CD3/B7-H2 for different time
points was assessed to induce the JNK pathway. No effect
could be observed in cell costimulated with α -CD3/α -
CD28. In CD4+ T cells costimulated with α -CD3/B7-H2
an increase in the ratio of phosphorylated JNK to total
JNK was observed (Figure 3C).
Effect of MAPK inhibitors on costimulated CD4+ T cells
These results indicated a role of MAPKs in the signaling
cascade precipitated from the costimulatory receptors
CD28 and ICOS leading to cytokine expression. To eluci-
date which MAPK is important for cytokine induction, we
first analyzed whether selective MAPK inhibitors were
able to inhibit α -CD3/B7-2 induced gene expression. To
this end, CD4+ T cells were preincubated with three selec-
tive MAPK inhibitors: SP600125 (selective inhibitor of c-
Jun N-terminal kinase (JNK)), U0126 (selective inhibitor
of MEK-1 and MEK2) and SB203580 (selective inhibitor
of p38 MAPK). These compounds were chosen based on
their pharmacological profile (high potency and specifi-
city) for these kinases [31-33]. Since the cytokine induc-
tion behaved similar on the protein and mRNA level (see
above), only mRNA was taken into consideration for
determination of IC50 values for inhibition of cytokines.
The JNK inhibitor did not affect induction of any cytokine
analyzed. The p38 inhibitor inhibited IL-2, IL-13 and IFNγ
with a similar IC50 of 3–7 µM, whereas IL-4 gene expres-
sion was not affected (Table 1). The MEK inhibitor U0126
inhibited IL-2 and IFNγ  gene expression with IC50 of
about 1 µM. IL-4 gene expression was not affected,
whereas IL-13 was potently inhibited with an IC50 of 0.18
µM (Table 1). Since ICOS costimulation also induced the
secretion of various cytokines and activated MAPKs, we
further analyzed whether this induction is influenced by
different pharmacological inhibitors of MAPKs in the
same manner as for α -CD3/B7-2 activation. The selective

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Induction of cytokines in CD4+ T cells by different costimulatory receptors Figure 1
Induction of cytokines in CD4+ T cells by different costimulatory receptors. Human CD4+ T cells were stimulated 
with various stimuli. (A) Cytokine mRNA level were determined after eight hours stimulation using real-time RT-PCR. mRNA 
level were normalized to β -actin and CD3 stimulated cells were set to 1. Each column represents mean ± s.e.mean of three dif-
ferent donors. (B) Cytokine protein level was determined in the supernatant by ELISA after twenty-four hours of stimulation. 
Each column represents mean ± s.e.mean of three different volunteers. *P < 0.05 (versus CD3 stimulated samples).Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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Time course of cytokine induction by costimulatory receptors Figure 2
Time course of cytokine induction by costimulatory receptors. Human CD4+ T cells were stimulated by α -CD3/B7-2 
(A) and α -CD3/B7-H2 (B) respectively and harvested after different time points. Cytokine mRNA level were determined using 
real-time RT-PCR. Levels were normalized to β -actin and unstimulated cells were set to 1. Each point and bar represents mean 
± s.e.mean of duplicates measurements of one donor. Similar results were obtained from three independent donors.Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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Activation of MAPKs in human primary CD4+ T-cells by costimulatory receptors Figure 3
Activation of MAPKs in human primary CD4+ T-cells by costimulatory receptors. Human CD4+ T cells were 
seeded at a concentration of 1 × 106/ml and stimulated with Dynal beads coated with α -CD3/B7-2 Fc (A) or α -CD3/B7-H2 Fc 
(B) for 0, 2, 5, 15, 60 or 120 min as indicated. Cells were harvested and cell extracts prepared. Cell extracts were analyzed by 
Western blot using either Anti-active pAb (upper row) or with corresponding antibodies that recognize both active and inac-
tive forms of each subfamily of MAPK. Results are representative of three experiments with similar results. (C) Activated JNK 
was detected by ELISA. CD4+ T cells were cultured in precoated 96-well plates at a concentration of 1 × 106 /ml. Cells were 
stimulated with α -CD3/B7-2 Fc and α -CD3/B7-H2 Fc for different times (1, 5, 15, 60 and 120 min). Following stimulation the 
cells were fixed. The phosphorylated form of JNK as well as the amount of total JNK was detected using an ELISA method. 
Results shown are representative for three independent experiments.
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p38 MAPK inhibitor (SB203580) affected cytokine syn-
thesis only at very high concentrations (>30 µM). The JNK
inhibitor SP600125 inhibited IL-2, IL-13 and IFNγ  dose
dependently at similar concentrations of about 1 µM
whereas IL-4 was not inhibited by this compound (Table
1). The ERK inhibitor U0126 inhibited IL-2, IL-13 and
IFNγ  dose dependently at similar concentrations of 0.1 to
0.4 µM whereas IL-4 was inhibited only at ten-fold higher
doses.
Effects of MAPK inhibitors in vivo
The finding that the MAPKs inhibitors very effectively
inhibited several cytokines in CD4+ T cells costimulated
through CD28 and ICOS, prompted us to investigate
whether these selective MAPKs inhibitors may be active in
an animal model of allergic asthma. BALB/c mice were
actively sensitized to ovalbumin and challenged by intra-
nasal application of ovalbumin solution. Different doses
of the three selective MAPKs inhibitors SP600125, U0126,
SB203580 were given intraperitoneally 2 hours before
challenge. After 4 days of challenge mice were killed and
bronchoalveolar lavage (BAL) was performed. Antigen
challenge caused a strong eosinophilic inflammation of
the lung and this was reflected in the cellular composition
of the lung lavage fluid. Compared with saline challenged
animals, the allergen challenge in sensitized animals led
to an increase in all leukocyte populations especially of
eosinophils in the lavage fluid (Figure 4). On average, the
total amount of leucocytes in the BAL of the positive con-
trol animals was 2.26 × 106 cells /ml (n = 7) and eosi-
nophils accounted for 60.16 % of the total cell count,
whereas in the saline challenged animals 0.16 × 106 cells
/ml (n = 7) could be detected, which contained no granu-
locytes or lymphocytes. The treatment of the animals with
SB203580 hardly affected leukocyte and eosinophils
numbers in the lavage fluid, even at very high doses (20
mg/kg) (Figure 4A). In contrast, the administration of
U0126 and SP600125 inhibited recruitment of the total
cell number in the bronchoalveolar lavage dose depend-
ently with an ED50 value of 2.5 mg/kg and 9 mg/kg respec-
tively. Absolute eosinophil and lymphocyte numbers
were also dose dependently inhibited by the ERK and JNK
inhibitors, whereas neutrophil numbers were not
affected. There were minor but not significant relative
changes in the different cell populations. The cytokine
protein levels in BAL fluid were below the detection limit
of the ELISA kits used. Therefore cytokine mRNA levels
were determined from BAL cells. SB203580 lacked also
any effect on the cytokine mRNA induced in BAL cells
(Figure 5A–C). In contrast, SP600125 and U0126 dose
dependently inhibited IL-5 mRNA induced in BAL cells
(Fig. 5D, G). Both compounds inhibited also IL-13 and
IFNγ mRNA at higher doses (Fig. 5 E, F, H, I).
Effects of MAPK inhibitors on serum OVA-specific IgE 
levels
We next determined whether MAPK inhibitors could
modify an ongoing OVA-specificTh2 response in vivo by
analyzing OVA-specific IgE levels. Serum was collected24
h after the last OVA challenge. Levels of OVA-specfic IgE,
was determined using ELISA. Substantial elevation OVA-
specific IgE was observed in serum from OVA-sensitized
and -challengedmice as compared with untreated mice
(Fig. 6). U0126 and SP600125 significantly lowered total
Table 1: IC50 values for the inhibition of cytokine mRNA synthesis by different MAPK inhibitors in CD28 or ICOS costimulated human 
CD4+ T cells. Human CD4+ T cells were preincubated with increasing concentrations of SP600125, U0126 and SB203580. The cells 
were then stimulated with beads coated with α -CD3/B7-2 fusion protein or α -CD3/B7-H2 fusion protein for 8 hours. Cytokine mRNA 
level were determined in triplicates using real time RT-PCR and were normalized to β -actin. Stimulated cells treated with DMSO 
were used as 100% control. IC50values were calculated for the different cytokines. Results represent mean ± s.e.m. for three different 
donors.
α -CD3/B7-2 stimulation
µM IL-2 IL-4 IL-13 IFNγ
U 0126 1.17 ± 0.97 no effect* 0.18 ± 0.14 0.72 ± 0.39
SB 203580 6.99 ± 4.57 no effect* 3.02 ± 1.14 4.15 ± 1.38
SP 600125 no effect* no effect* no effect* no effect*
α -CD3/B7-H2 stimulation
µM IL2 IL4 IL13 IFNγ
U 0126 0.11 ± 0.03 1.29 ± 0.96 0.31 ± 0.09 0.14 ± 0.08
SB 203580 no effect* no effect* no effect* 6.93 ± 2.47
SP 600125 1.25 ± 0.18 no effect* 1.33 ± 0.36 0.79 ± 0.35
*concentrations up to 30 µM were testedRespiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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Effects of MAPK inhibitors in vivo Figure 4
Effects of MAPK inhibitors in vivo. Actively intraperitoneally sensitized mice were challenged by intranasally administration 
of ovalbumin. SB203580 (Figure A), SP600125 (Figure B) and U0126 (Figure C) were given intraperitoneally two hours prior to 
ovalbumin challenge. After 4 days of challenge bronchoalveolar lavage was performed. Total cell number in BAL and differential 
cell count on cytospin preparations was assessed. OVA challenged vehicle-treated animals were taken as a positive control. 
Each column represents mean ± s.e.mean. n = 5 mice per group. *p < 0.05 (drug treated versus OVA challenged vehicle (posi-
tive) control), **p < 0.005 (drug treated versus OVA challenged vehicle (positive) control). ++ p < 0.005 (OVA challenged (pos-
itive) versus saline challenged (negative) control).Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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OVA-specific IgE levels, whereas SB203580 did not affect
OVA-specific IgE levels.
Effects of MAPK inhibitors on lung inflammation in vivo
On separate experiments, lung tissue was collected 24
hours after the last challenge. Ovalbumin challenge
induced marked infiltration of inflammatory cells into the
peribronchial and perivasular tissue as compared with
saline challenge (Figure 7 A, B). The majority of the infil-
trated inflammatory cells were eosinophils as detected in
the May-Günwald Giemsa stain (data not shown). MAPK
inhibitors had different effects on peribronchial inflam-
mation. The inflammatory score (calculated as described
in Methods) decreased significantly after administration
of 20 mg/kg ERK or JNK inhibitor, whereas inhibition of
p38 had no influence on peribronchial inflammation
(Figure 7G). The allergen challenge induced mucus secre-
tion was detected with periodic acid-Schiff stain counter-
stained with hematoxylin (Figure 7A, B). The percentage
of PAS-positive mucus-containing epithelial cells
decreased as an effect of ERK or JNK inhibition (Figure
7D, E, G). The p38 inhibitor had no effect on mucus pro-
duction (Figure 7C, G).
Effects of combined administration of MAPK inhibitors
Since the three MAPKs are part of different signaling cas-
cades with different upstream and downstream media-
tors, we asked whether the combination of two MAPK
inhibitors may have synergistic effects on the induction of
cytokines in CD4+T cells. The simultaneous addition of
SB203580 (5 µM) and SP600125 (3 µM) did not cause
any synergistic effect. Unexpectedly, the simultaneous
Effects of MAPK inhibitors on BAL cytokine levels Figure 5
Effects of MAPK inhibitors on BAL cytokine levels. Cells were recovered from bronchoalveolar lavage by centrifugation 
and RNA was prepared from the cell pellet. Cytokine mRNA level were determined using real-time RT-PCR and were normal-
ized to β -actin. Each column represents mean ± s.e.mean. n = 5 mice per group. n.d. – not detectable. *p < 0.05 (versus OVA 
challenged positive control), +p < 0.05 (negative versus positive control)Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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administration of increasing concentrations of U0126
(0.01 µM to 30 µM) and SB 203580 to α -CD3/α -B7-2
(Figure 8A, B) and α -CD3/B7-H2 (Figure 8C and 8D)
stimulated CD4+ T cells led to a shift to the right of the
dose-response curve for U0126 compared to the adminis-
tration of U 0126 alone. The dose for SB203580 was 10
µM for ICOS costimulation and 1 µM for CD28 costimu-
lation, respectively. This was reflected by an increase in
the corresponding IC50 values (Table 2). In contrast, the
addition of SP600125 (0.3 µM for ICOS costimulation
and 1.5 µM for CD28 costimulation) did not change the
dose response curve for U0126 (Figure 8). Since we
observed for the combination SB203560 and U0126 only
unforeseen effects in vitro, we analyzed this combination
in vivo. The simultaneous treatment of the animals with 5
mg/kg SB203580 and 5 mg/kg U0126 (Figure 9) dimin-
ished the inhibition of late phase eosinophilia by the
solely administration of the ERK inhibitor. There were
minor and not significant change in the relative numbers
of the populations counted in the BAL. This effect could
also be observed measuring cytokine mRNA levels in the
BAL cells. Treatment of the animals with SB203580 antag-
onized the inhibiting effect of U0126 on IL-5, IL-13 and
IFNγ  mRNA level (Figure 10). The effect of the combined
administration of ERK inhibitor and p38 inhibitor on
lung histology had the same effect as observed in vitro, as
well as on the cellular composition of the BAL. The p38
inhibitor abolished the effect of ERK inhibition when
administered simultaneously compared to administration
of ERK inhibitor alone (Figure 7F, G). Furthermore, OVA-
specific IgE Level in the serum of mice treated with the
combination of the ERK and p38 inhibitor were higher
than in mice treated with the ERK inhibitor alone (Figure
6).
Discussion
Costimulation is essential for the full activation of CD4+ T
cells. In this study, we analyzed the induction and
regulation of Th1 and Th2 cytokines in CD4+ T cells upon
engagement of different costimulatory receptors. Beads
with defined combinations of surface receptor stimulating
antibodies and costimulatory receptor ligands were
applied to induce cytokine synthesis. Ligation of two cos-
timulatory receptors, CD28 and ICOS, augmented TCR
activation and this in part is due to MAPK activation. The
effects of pharmacological inhibitors of three different
MAPKs on cytokines induced by α -CD3/B7-2 or α -CD3/
B7-2 were investigated. Using these compounds, we were
able to elucidate different MAPK signaling pathways lead-
ing to cytokines synthesis in dependence on the costimu-
latory receptor engaged. We tested these compounds in an
animal model of asthma in which the ERK inhibitor
U0126 and the JNK inhibitor SP600125 were able to
reduce the influx of eosinophils into the lungs of
sensitized and challenged mice. We found no synergistic
effect of any combination of these MAPK inhibitors.
Unexpectedly, SB203580 antagonized the in vitro and in
vivo action of U0126.
For optimal activation, CD4+ T cells require specific anti-
gen recognition by the TCR and additional signals
(collectively called costimulatory signals), delivered by
the same antigen-presenting cell [34]. In the absence of
costimulation, lymphocytes fail to respond effectively and
are rendered anergic [35]. CD28 is the best-characterized
costimulatory receptor and constitutively present on the
surface of T cells (reviewed in [12]). CD28 is activated by
B7-1 and B7-2 counter-receptors on antigen-presenting
cells. Its signaling contributes to the overall strength of T
cell activation [36]. However, new B7- and CD28-like
molecules have recently been discovered and new path-
ways have been delineated that seem to be important for
regulating the responses of previously activated T cells
[37]. Some B7 homologues have unknown receptors,
indicating that other immunoregulatory pathways remain
to be described. We established an in vitro test system to
analyze to role of each coreceptor. To this end, we
conjugated beads with defined combinations of α -CD3
and B7 counterreceptors. In line with previous reports
Effects of MAPK inhibitors on OVA-specific IgE antibody lev- els in the serum Figure 6
Effects of MAPK inhibitors on OVA-specific IgE anti-
body levels in the serum. Mouse serum was collected 24 
h after the last OVA challenge. Samples were obtained from 
saline- (negative) or OVA-challenged mice in the absence 
(positive) or presence of MAPK inhibitors: SB203580 (20 mg/
kg), U0126 (20 mg/kg), SP600125 (20 mg/kg) or of the com-
bination of U0126 (5 mg/kg) plus SB203580 (5 mg/kg). Serum 
titers for OVA-specific IgE antibodies were measured by 
ELISA as described in methods. Each column represents 
mean ± s.e.mean. n = 5 mice per group. *p < 0.05 (versus 
OVA challenged positive control), +p < 0.05 (negative versus 
positive control)Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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described above we found that CD28 ligation augments
the synthesis of all T cell derived cytokines. Similar results
were obtained by ligating ICOS via its counter receptor
ICOS-L (B7-H2). The effects of ICOS signals on T cell pro-
liferation and IL-2 production were reported to be modest
in comparison with those of CD28 [16]. However, ICOS
costimulation is equivalent to that mediated by CD28
costimulation for the production of effector cytokines like
IFNγ , IL-4, IL-10 and IL-13. IL-5 was not detected. It has
been shown, that efficient in vitro IL-5 production needs
elevated cAMP level in addition to TCR stimulation [38].
There was no difference in the strength of induction of
Th2 compared with Th1 cytokines for CD28 and ICOS
costimulation. Conflicting data has been reported about
the function of PD-1. The engagement of PD-1 by its
specific ligands, B7-H1 (PD-L1) or B7-DC (PD-L2) was
reported to inhibit T and B cell proliferation and cytokine
production [39,40]. In our test system engagement of PD-
1 by ligation with B7-H1 neither augmented nor inhibited
cytokine synthesis.
Histology of lung inflammation Figure 7
Histology of lung inflammation. Representative sections of the lungs are shown. Sections are periodic acid-Schiff stained 
and counterstained with haematoxylin for analysis of mucin-containing cells. Tissue was examined by light microscopy (original 
magnification 20×), zoomed inset delineates PAS+ epithelial cells (100×). Lung sections were obtained from saline- (A) or 
OVA- (B, C, D, E, F) challenged mice in the absence (A, B) or presence of MAPK inhibitors: SB 203580 (20 mg/kg) (C), U 0126 
(20 mg/kg) (D), SP 600125 (20 mg/kg) (E) or of the combination of U 0126 (5 mg/kg) plus SB 203580 (5 mg/kg) (F). Peribron-
chial inflammation and the abundance of PAS-positive mucus-containing cells were determined by applying the scores as 
described in methods (G). The scores described in methods were applied to ten bronchi for each animal and mean and stand-
ard deviation were determined for all the animals in a group (n = 5). *P < 0.05 and **P < 0.01 compared with positive control 
group.Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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Activation of MAPK family members by CD28 and ICOS
may contribute to their costimulatory activity. To analyze
whether different signaling cascades are precipitated by
the different coreceptors, their ability to activate different
MAPK pathways was determined. Since only CD28 and
ICOS activation augmented cytokine synthesis we focused
Effects of combined administration of MAPK inhibitors in vitro Figure 8
Effects of combined administration of MAPK inhibitors in vitro. Human CD4+ T cells were preincubated either with 
increasing doses of U0126 alone (solid line) or in combination with SP 600125 (dashed line) of with SB 203580 (dotted line). 
Doses of the MAPK inhibitors are specitied in the text. After that, cells were stimulated with α -CD3/B7-2 Fc (A, B) or α -CD3/
B7-H2 Fc (C, D) for 8 hours. IFNγ  (A, C) and IL-13 (B, D) cytokine mRNA was measured by real-time RT-PCR. Dose-response 
curves were determined and IC50 values were calculated. Data are representative of three different donors.
Table 2: IC50 values for the inhibition of cytokine mRNA synthesis by combined administration of MAPK inhibitors in vitro. IC50values 
were calculated from data shown in Figure 8.
µMI F N γ  (U0126) IFNγ  
(U0126+SB203580)
IL-13 (U0126) IL-13 
(U0126+SB203580)
α -CD3/B7-2 0.29 0.68 0.28 0.97
α -CD3/B7-H2 0.19 1.14 0.21 0.73Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
Page 15 of 19
(page number not for citation purposes)
our analyses on these receptors. We analyzed the signaling
pathways of ERK1/2, JNK, and p38 MAP kinase, during
the primary activation of human T-cells, costimulated
with ICOS or CD28. ERK1/2 and p38 kinase were mark-
edly activated by both CD28- and ICOS-mediated costim-
ulation. In our cellular assay system the activation of ERK
has a role in T-cell activation via CD28 and ICOS. The acti-
vation of ERK by CD28 is mediated by binding of SOS to
the YMNM motif of the intracellular domain of CD28
[41]. The YMNM motif is not conserved in ICOS, the
sequence being YMFM, and amino-acid substitutions in
this motif results in a failure to associate with Grb2
[16,42]. Therefore it is currently unclear, how ICOS is able
to activate ERK.
Previous studies of p38 MAP kinase in human purified T
cells [43] and in the CD4+ subset [7] clearly demonstrated
the involvement of p38 MAP kinase in the cell activation
through TCR and CD28 costimulation signal pathways.
However, little is known about this MAP kinase in ICOS
costimulated T cells. In our cellular assay activation of p38
MAPK by ICOS was detected. This is in line with recent
reports, in which ICOS ligation synergized with TCR sig-
nals for activation of the ERK and p38 MAP kinases
[44,45].
While enhanced activityof JNK is an absolute necessity for
regulation of IL-2 geneexpression in T cell lines [46], a
defect in JNK signalingwas claimed to be involved in T cell
differentiation, but notin T cell activation in vivo, i.e. in
JNK-deficient animals [47]. This corresponds to our
results with human T cells, where JNK was found not to be
activated after CD28 costimulation. Conflicting reports
appeared about the ability of ICOS to activate the JNK
pathway. Parry et al. reported that only CD28 but not
ICOS costimulation activated c-jun N-terminal kinase
[48]. Arimura et al. reported that the cross-linking of ICOS
induced much less phosphorylation of JNK than did the
Effects of combined administration of MAPK inhibitors in vivo Figure 9
Effects of combined administration of MAPK inhibitors in vivo. Late phase eosinophilia was induced in mice pretreated 
either with 5 mg/kg U0126 and 5 mg/kg SB 203580 or with the combination thereof. BAL was performed and total cell number 
and differential leukocyte count was determined. OVA challenged vehicle-treated animals were taken as positive control. Each 
column represents mean ± s.e.mean. n = 5 mice per group. *p < 0.05 (versus OVA challenged vehicle control), +p < 0.05 (ver-
sus U0126 alone).Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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cross-linking of CD28 [49]. In our cellular assay system
we found that ICOS activated the JNK pathway. However,
this was only detected by using a sensitive ELISA based
assay indicating a very low expression of JNK in primary
human T cells. Alltogether, whereas p38 and ERK are
consistently found to be activated after CD28 and ICOS
costimulation, the activation of JNK appeared only after
ICOS costimulation.
In order to elucidate which of the activated MAP kinases
are important for cytokine induction after T cell activation
and costimulation we employed specific inhibitors of the
different MAPKs in our cellular assay system. These com-
pounds were chosen based on their pharmacological
profile (high potency and specificity) for these three
kinases [31-33]. The p38 inhibitor SB203580 and the ERK
inhibitor U0126 inhibited IL-2, IL-13 and IFNγ  in CD28
costimulated T-cells. IL-4 induction, in contrast, was not
affected by these inhibitors. In line with our observations,
that JNK does not become activated by CD28
costimulation, the JNK inhibitor did not affect cytokine
induction in CD28 costimulated T cells. Only one report
analyzed the effect of a p38 inhibitor in primary human
CD4+ T cells. There SB203580 blocked human CD4 T cell
production of IL-4, IL-5, TNF-, and IFN-, but not IL-2, in
response to CD3 and CD28 stimulation [7]. This differ-
ence is most likely due to different experimental protocols
and the use of a different T cell population. While U0126
was never tested to inhibit human T cell cytokine produc-
tion, in the first description of the JNK inhibitor
SP600125, its effect on polarized Th1 and Th2 cells was
described. There Th1 cytokines and some Th2 cytokines
but not IL-4 was inhibited by this compound [32]. It is
tempting to speculate, that the polarization of the T cells
rendered them susceptible to JNK inhibition. Different
observations were made in ICOS costimulated T cells. For
human T cells, it has only been reported, that U0126
blocked the proliferation of T-cells and the transcription
of IL-2 following costimulation by ICOS in human T cell
[45]. We found, that the p38 inhibitor was not effective,
but the JNK inhibitor inhibited IL-2, IL-13 and IFNγ . The
ERK inhibitor U0126 inhibited all cytokines with similar
efficiency as in CD28 costimulated T cells. Together these
data indicates that in human T cells ICOS precipitates
MAPK signaling cascades differentially compared to
murine T cells. More interestingly, our inhibitor studies
revealed that not every MAPK signaling cascade activated
by costimulation is necessary for cytokine synthesis.
The sensitivity of CD4+ T cells to various MAPK inhibitors
prompted us to analyze these compounds in an animal
model of asthma. The p38 inhibitor SB203580 did not
affect airway inflammation in our model. Conflicting data
about the action of p38 inhibitors in asthma models have
been reported in the literature. Similar to our results, one
study found no effect of SB203580 in rats [50]. In con-
trast, Underwood et al. demonstrated anti-allergic activity
using a novel second-generation p38 MAPK inhibitor
[51]. Either increased specificity of this new inhibitor or
better bioavailability of this compound may explain its
effect in vivo. In contrast to the p38 inhibitor, the ERK as
well as the JNK inhibitor dose dependently decreased
allergen induced airway eosinophilia in our model. This
anti-inflammatory effect of the ERK and the JNK inhibitor
Effects of combined MAPK inhibitors on BAL cytokine levels Figure 10
Effects of combined MAPK inhibitors on BAL cytokine levels. Cells were recovered from bronchoalveolar lavage by 
centrifugation and RNA was prepared from the cell pellet. Cytokine mRNA level were determined using real-time RT-PCR and 
were normalized to β -actin. Each column represents mean ± s.e.mean. n = 5 mice per group. *p < 0.05 (versus OVA challenged 
vehicle control), +p < 0.05 (versus U0126 alone).Respiratory Research 2005, 6:36 http://respiratory-research.com/content/6/1/36
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was also detected by measuring peribronchial inflamma-
tion and mucus production. Elevated serum IgE is a hall-
mark of a Th2 immune response. Our data showed that
serum levels of OVA-specific IgE were also substantially
reduced by U0126 and SP600125, whereas no significant
inhibition was observed by SB203580. This extends our
previous findings, where 10 mg/kg of U0126 were found
to be effective in a rat asthma model [28]. During the
preparation of the manuscript it was reported that 30 mg/
kg SP600125 inhibited airway eosinophilia in rats [52].
This supports our finding, that targeting JNK reduces aller-
gic airway inflammation.
The inhibitory effect could also be observed by the reduc-
tion of cytokine mRNA level. However, the inhibition was
not selective for Th2 cytokines. The induction of IFNγ  in
BAL cells was also inhibited by U0126 and SP600125.
This is in line with our findings described above, that
costimulation of T cells induces Th1 as well as Th2
cytokines and that MAPK inhibitors are also effective in
inhibiting IFNγ . This may be beneficial for the anti-
inflammatory effect in the asthma model. It has been
shown, that in IFNγ  knockout mice less pronounced aller-
gic symptoms such as antigen-specificIgE, eosinophilic
infiltration, and airway hyperresponsiveness occur [53].
Therefore, it seems likely that endogenous IFNγ  is
necessaryfor optimal IgE production also during a second-
ary response.
The in vivo profile of MAPK inhibitors reflects the in vitro
profile of ICOS costimulated T cells: ERK and JNK inhibi-
tors are effective whereas the p38 inhibitor is not. In con-
trast, the inhibitory profile of CD28 costimulated T cells is
different. There p38 is effective, while the JNK inhibitor is
not. In line with this, it has been shown, that ICOS plays
an important role in the Th2 effector responses in the
lungs, in that inhibition of ICOS suppresses lung
inflammation and Th2 cytokine production [54]. Simi-
larly, ICOS-L-Fc augments lung inflammation and the
production of cytokines [55]. Together these data indicate
the importance of ICOS costimulation in the allergic lung
response. Therefore, targeting signaling pathways
precipitated by ICOS should dampen the allergic lung
inflammation.
Since the three MAPKs are part of different signaling cas-
cades with different upstream and downstream media-
tors, we asked whether the combination of two MAPK
inhibitors may have synergistic effects on the induction of
cytokines in CD4+T cells. Our in vitro studies did not
reveal any such synergistic effect regardless of the combi-
nation used. However, we could observe that the simulta-
neous administration of increasing concentrations of
U0126 and 1 µM SB203580 to α -CD3/α -CD28 and α -
CD3/α -ICOS stimulated CD4+ T cells led to a right-shift
of the dose-response curve for U0126 compared to the
administration of U0126 alone. We analyzed this combi-
nation also in vivo. Whereas treatment of the animals with
U0126 alone inhibited late phase eosinophilia markedly
as in previous experiments the concomitant treatment
with SB203580 diminished the effect of U0126 almost
completely. To our knowledge no in vitro or in vivo studies
reported the simultaneous addition of two MAPK
inhibitors in T cell activation studies or asthma models.
Currently, we investigate the mechanism for this antago-
nistic action.
Conclusion
Different MAPK signaling pathways are activated in T cells
dependent on the costimulatory receptor engaged. The
MAP kinase ERK is important for both stimuli. p38 MAPK
activation is important for CD28 induced cytokine syn-
thesis, whereas JNK is important for ICOS induced
cytokine synthesis. The different regulation can be
exploited to find new specifically targeted drugs aimed for
diseases where different costimulatory molecules play an
important pathophysiological role. We could demon-
strate for the first time that inhibition of the JNK cascade
is a therapeutic option for asthma. The specific JNK inhib-
itor SP 600125 reduced the influx of eosinophils in an
animal model of asthma. The development of more spe-
cific MEK-ERK and JNK-targeted drugs would support this
approach to treat T cell dominated diseases such as
asthma.
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